ONCOLOGY: Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
Audio Journal of Oncology, February 26th, 2008
Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
MARTIN DREYLING, University Hospital Grosshaden, Munich
REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.
Audio Medica News - Medical News Interviews
enFebruary 29, 2008